Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelial-to-mesenchymal transition, inflammation and angiogenesis

Nintedanib, an Food and Drug Administration (FDA) approved multiple tyrosine kinase inhibitor, exhibits an anti-fibrotic effect in lung and kidneys. Its effect on peritoneal fibrosis remains unexplored. In this study, we found that nintedanib administration lessened chlorhexidine gluconate (CG)-indu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of cellular and molecular medicine 2021-07, Vol.25 (13), p.6103-6114
Hauptverfasser:	Liu, Feng, Yu, Chao, Qin, Huan, Zhang, Shenglei, Fang, Lu, Wang, Yi, Wang, Jun, Cui, Binbin, Hu, Susie, Liu, Na, Zhuang, Shougang
Format:	Artikel
Sprache:	eng
Schlagworte:	Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!